Background: Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (IPTp-SP). However, limited data exist on how IPTp regimens impact malaria risk during infancy. We conducted a double-blinded randomized controlled trial to test the hypothesis that children born to mothers given IPTp-DP would have a lower incidence of malaria during infancy compared to children born to mothers who received IPTp-SP.
Methods and Findings: We compared malaria metrics among children in Tororo, Uganda born to women randomized to IPTp-SP given every 8 weeks (SP8w, n=100), IPTp-DP every 8 weeks (DP8w, n=44) or IPTp-DP every 4 weeks (DP4w, n=47). After birth, children were given chemoprevention with DP every 12 weeks from 8 weeks to 2 years of age. The primary outcome was incidence of malaria during the first two years of life. Results are reported after adjustment for clustering (twin gestation) and potential confounders (maternal age, gravidity, and maternal parasitemia status at enrolment).The study took place between June 2014 and May 2017. Compared to children whose mothers were randomized to IPTp-SP8w (0.24 episodes per person year (PPY)), the incidence of malaria was higher in children born to mothers who received IPTp-DP4w (0.42 episodes PPY, adjusted incidence rate ratio (aIRR) 1.92; 95% CI 1.00-3.65, p=0.049) and non-significantly higher in children born to mothers who received IPT-DP8w (0.30 episodes PPY, aIRR 1.44; 95% CI, 0.68-3.05; p=0.34). However, these associations were modified by infant sex. Female children whose mothers were randomized to IPTp-DP4w had an apparently 4-fold higher incidence of malaria compared to female children whose mothers were randomized to IPTp-SP8w (0.65 vs 0.20 episodes PPY, aIRR 4.39, 95% CI 1.87-10.3, P=0.001), but no significant association was observed in male children (0.20 vs. 0.28 episodes PPY, aIRR 0.66, 95% CI 0.25-1.75, P=0.42). Non-significant increases in malaria incidence were observed among female, but not male, children born to mothers who received DP8w vs SP8w. In exploratory analyses, levels of malaria-specific antibodies in cord blood were similar between IPTp groups and sex. However, female children whose mothers were randomized to IPTp-DP4w had lower mean piperaquine levels during infancy compared to female children whose mothers received IPTp-SP8w (coef 0.81, 95% CI 0.65-1.00, P=0.048) and male children whose mothers received IPTp-DP4w (coef 0.72, 95% CI 0.57-0.91, P=0.006). There were no significant sex-specific differences in piperaquine levels among children whose mothers were randomized to IPTp-SP8w or IPTp-DP8w. The main limitations were small sample size and childhood provision of DP every 12 weeks in infancy.
Conclusions: Contrary to our hypothesis, preventing malaria in pregnancy with IPTp-DP in the context of chemoprevention with DP during infancy does not lead to a reduced incidence of malaria in childhood; in this setting, it may be associated with an increased incidence of malaria in females. Future studies are needed to better understand the biological mechanisms of in utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs for treatment and prevention during infancy.
Trial registration: ClinicalTrials.gov number NCT02163447.
